Golden State Wealth Management’s Sonnet BioTherapeutics SONN Stock Holding History

Golden State Wealth Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-202	Closed	-$925	–	1751
2025 Q3	$925	Buy	+202	New	+$896	﹤0.01%	1513

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Golden State Wealth Management's SONN Position: Q4 2025 in Review

Golden State Wealth Management sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 202 shares — an estimated $925 sold.

Golden State Wealth Management first reported a position in SONN in Q3 2025 and held it in 1 quarter. The position peaked at $925 in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Golden State Wealth Management reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Golden State Wealth Management sold 202 Sonnet BioTherapeutics shares in Q4 2025, an estimated $925.
Golden State Wealth Management first reported a position in Sonnet BioTherapeutics in Q3 2025 and held it in 1 quarter.
Golden State Wealth Management's Sonnet BioTherapeutics position peaked at $925 in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Golden State Wealth Management's 13F filing for Q4 2025, filed 13 Feb 2026.